ARROWHEAD PHARMACEUTICALS, INC. Investment Income, Interest and Dividend
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Investment Income, Interest and Dividend of $16.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterestAndDividend · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. investment income, interest and dividend for the quarter ending 2026-06-30 was $16.93M, a 53.69% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, interest and dividend for the quarter ending 2026-03-31 was $16.87M, a 75.44% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, interest and dividend for the quarter ending 2025-12-31 was $9.69M, a 27.47% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, interest and dividend for the quarter ending 2025-09-30 was $9.05M, a 26.26% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, interest and dividend for fiscal 2025 was $37.29M, a 64.12% increase from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, interest and dividend for fiscal 2024 was $22.72M, a 48.51% increase from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, interest and dividend for fiscal 2023 was $15.30M, a 203.97% increase from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, interest and dividend for fiscal 2022 was $5.03M, a 17.76% decline from fiscal 2021.
| Period end | Investment Income, Interest and Dividend 3 month | Investment Income, Interest and Dividend 6 month | Investment Income, Interest and Dividend 9 month | Investment Income, Interest and Dividend 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.93M 10-Q · filed 2026-08-04 | $33.80M derived: sum of 2 quarters · filed 2026-08-04 | $43.50M 10-Q · filed 2026-08-04 | $52.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $16.87M 10-Q · filed 2026-05-07 | $26.56M 10-Q · filed 2026-05-07 | $35.61M derived: sum of 3 quarters · filed 2026-05-07 | $46.63M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $9.69M 10-Q · filed 2026-02-05 | $18.74M derived: sum of 2 quarters · filed 2026-02-05 | $29.76M derived: sum of 3 quarters · filed 2026-08-04 | $39.38M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-09-30 | $9.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $20.07M derived: sum of 2 quarters · filed 2026-08-04 | $29.69M derived: sum of 3 quarters · filed 2026-08-04 | $37.29M 10-K · filed 2025-11-25 |
| 2025-06-30 | $11.02M 10-Q · filed 2026-08-04 | $20.63M derived: sum of 2 quarters · filed 2026-08-04 | $28.24M 10-Q · filed 2026-08-04 | $35.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $9.62M 10-Q · filed 2026-05-07 | $17.22M 10-Q · filed 2026-05-07 | $24.39M derived: sum of 3 quarters · filed 2026-05-07 | $30.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.60M 10-Q · filed 2026-02-05 | $14.77M derived: sum of 2 quarters · filed 2026-02-05 | $21.27M derived: sum of 3 quarters · filed 2026-02-05 | $27.52M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $13.67M derived: sum of 2 quarters · filed 2025-11-25 | $19.92M derived: sum of 3 quarters · filed 2025-11-25 | $22.72M 10-K · filed 2025-11-25 |
| 2024-06-30 | $6.50M 10-Q · filed 2025-08-07 | $12.75M derived: sum of 2 quarters · filed 2025-08-07 | $15.55M 10-Q · filed 2025-08-07 | $19.43M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $6.25M 10-Q · filed 2025-05-12 | $9.05M 10-Q · filed 2025-05-12 | $12.94M derived: sum of 3 quarters · filed 2025-11-25 | $17.11M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $2.80M 10-Q · filed 2025-02-10 | $6.69M derived: sum of 2 quarters · filed 2025-11-25 | $10.86M derived: sum of 3 quarters · filed 2025-11-25 | $15.42M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $8.06M derived: sum of 2 quarters · filed 2025-11-25 | $12.62M derived: sum of 3 quarters · filed 2025-11-25 | $15.30M 10-K · filed 2025-11-25 |
| 2023-06-30 | $4.17M 10-Q · filed 2024-08-08 | $8.73M derived: sum of 2 quarters · filed 2024-08-08 | $11.41M 10-Q · filed 2024-08-08 | $13.00M derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-03-31 | $4.56M 10-Q · filed 2024-05-09 | $7.24M 10-Q · filed 2024-05-09 | $8.82M derived: sum of 3 quarters · filed 2024-11-26 | $10.06M derived: sum of 4 quarters · filed 2024-11-26 |
| 2022-12-31 | $2.68M 10-Q · filed 2024-02-06 | $4.26M derived: sum of 2 quarters · filed 2024-11-26 | $5.50M derived: sum of 3 quarters · filed 2024-11-26 | $6.56M derived: sum of 4 quarters · filed 2024-11-26 |
| 2022-09-30 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $2.82M derived: sum of 2 quarters · filed 2024-11-26 | $3.88M derived: sum of 3 quarters · filed 2024-11-26 | $5.03M 10-K · filed 2024-11-26 |
| 2022-06-30 | $1.24M 10-Q · filed 2023-08-07 | $2.29M derived: sum of 2 quarters · filed 2023-08-07 | $3.45M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $1.05M 10-Q · filed 2023-05-02 | $2.21M 10-Q · filed 2023-05-02 | ||
| 2021-09-30 | $6.12M 10-K · filed 2023-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |